Form 4: Amicus Therapeutics CLO Reports Stock Dispositions

Amicus Therapeutics' Chief Legal Officer, Ellen Rosenberg, reported the disposition of common stock shares in routine transactions.

Summary

• Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, Inc. (FOLD), reported changes in her beneficial ownership of common stock.
• On January 2, 2026, Ms. Rosenberg disposed of 13,426 shares of common stock at a price of $14.27 per share.
• Following this transaction, her direct beneficial ownership stood at 494,284 shares.
• On January 3, 2026, an additional 29,683 shares of common stock were disposed of at a price of $14.27 per share.
• After the second transaction, Ms. Rosenberg's direct beneficial ownership decreased to 464,601 shares.
• The transactions were marked with transaction code 'F', typically indicating a disposition to satisfy tax withholding obligations upon the vesting of restricted stock or the exercise of options.
• Ms. Rosenberg also indirectly beneficially owns 15,000 shares of common stock through her spouse.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock dispositions, which are generally neutral in sentiment as they often relate to tax obligations or personal financial planning rather than a change in company outlook.

Negatives

• A reduction in direct beneficial ownership by a key executive, although often for routine tax purposes.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider transactions and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• Ellen Rosenberg indirectly beneficially owns 15,000 shares of common stock through her spouse.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, which is generally not considered a significant indicator of company performance or future prospects given the routine nature of such transactions.

Key Dates

Recommendation

This Form 4 filing details routine insider stock dispositions, which do not provide new information regarding the company's operational performance or strategic direction. Such transactions are common for executives and typically do not warrant a change in investment thesis based solely on this disclosure.

Keywords

Amicus Therapeutics, FOLD, Ellen Rosenberg, Chief Legal Officer, Insider Trading, Form 4, Stock Disposition, Beneficial Ownership